Publication|Articles|November 11, 2026

Supplements

  • Pharmacist Management of HIV Treatment for Appropriate VS Adults: BIC/LEN

Pharmacist Management of HIV Treatment for Appropriate VS Adults: BIC/LEN

Key Takeaways

  • Sponsorship by a manufacturer can influence topic selection, messaging priorities, and prominence of favorable efficacy/safety narratives, even when medical writing is compliant.
  • Verification should rely on original trial publications, regulatory labels, and major guidelines, with attention to absolute benefit, OS maturity, and clinically meaningful effect sizes.
SHOW MORE

This article is sponsored by Gilead Sciences, Inc.

This article is sponsored by Gilead Sciences, Inc.

1. INTRODUCTION: WHAT TO KNOW ABOUT BIC/LEN IN PHARMACY PRACTICE

HIV treatment has advanced significantly over the past few decades. In 2006, the US Food and Drug Administration (FDA) approved the first once-daily single-tablet regimen (STR) for HIV, reducing daily pill burden for people with HIV (PWH).1-3

According to US Department of Health and Human Services guidelines, maintaining viral suppression to undetectable levels (HIV-1 RNA < 200 copies/mL) with antiretroviral therapy (ART) has been associated with reduced HIV sexual transmission rates when ART is taken as prescribed.4

With ART, the life expectancy for people with HIV is approaching that of the general population. As more PWH age, the population of older adults with HIV continues to grow.5,6 Today, more people are aging with HIV, managing comorbidities and concomitant medications, and actively participating in a shared decision-making model with their care team.5-8

Continuing the progress achieved in HIV care, the FDA on August 27, 2026, approved BIXLENVOTM (bictegravir/lenacapavir).9 BIXLENVO, a 2-drug combination of bictegravir (BIC), an HIV type 1 (HIV-1) integrase strand transfer inhibitor (INSTI), and lenacapavir (LEN), an HIV-1 capsid inhibitor, is indicated as a complete regimen for the treatment of HIV-1 in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no known or suspected resistance to the individual components of BIXLENVO.9 At approval, BIC/LEN is the smallest STR (after initiation doses) for the treatment of appropriate virally suppressed HIV in adults (switch option). Prescribing highlights are below.

These highlights do not include all the information needed to use BIXLENVO safely and effectively.9

Indications and Usage

BIXLENVO, a 2-drug combination of BIC, an HIV-1 integrase strand transfer inhibitor (INSTI), and LEN, an HIV-1 capsid inhibitor, is indicated as a complete regimen for the treatment of HIV-1 in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA < 50 copies per mL) on a stable antiretroviral regimen with no known or suspected resistance to the individual components of BIXLENVO.

Dosage and Administration

  • Recommended dosage: 2-day initiation regimen of BIXLENVO plus oral SUNLENCA. (lenacapavir), followed by a maintenance regimen of BIXLENVO. Tablets may be taken with or without food.

Missed Initiation Dose

During the initiation period, if the day 1 or day 2 doses of BIXLENVO or SUNLENCA are missed, patients should take them as soon as possible. Patients should not take day 1 and day 2 doses of SUNLENCA on the same day.

Missed Maintenance Dose

If a maintenance dose of BIXLENVO is missed, patients should take it as soon as possible. If more than 7 days have elapsed since the last maintenance dose, restart the initiation dosage regimen from day 1, if clinically appropriate to continue BIXLENVO treatment.

Dosage Forms and Strengths

Tablets: 75-mg BIC and 50-mg LEN

Contraindications

  • Concomitant administration of BIXLENVO is contraindicated with:
  • Dofetilide

Strong CYP3A inducers

Adverse Reactions

  • Most common adverse reactions (incidence greater than or equal to 2%, all grades) are headache, nausea, and diarrhea.
  • To report suspected adverse reactions, contact Gilead Sciences, Inc. at 1-800-GILEAD-5 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Drug Interactions

  • Because BIXLENVO is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended.
  • Consult the US prescribing information prior to and during treatment for important drug interactions.

Pharmacy teams play an integral role in helping patients achieve optimal health outcomes.10 Education and awareness of BIC/LEN may help equip pharmacists to support clinical and shared decision-making by enhancing understanding of drug-drug interactions, the dosing recommendation, including the rationale and importance of the 2-day loading dose, management of missed doses, and administration requirements for SUNLENCA. and BIXLENVO.11 Understanding the pharmacology, metabolic pathways, clinical efficacy, safety and rationale for the development of BIC/LEN informs its appropriate use in clinical practice and supports the delivery of safe, effective patient care.

2. HIV TREATMENT LANDSCAPE: WHERE BIC/LEN WAS DESIGNED TO FIT

The ARTISTRY clinical trial program was designed to evaluate the efficacy and safety of BIC/LEN vs stable baseline regimen in adults with HIV. The two phase 3 registrational trials, ARTISTRY-1 and ARTISTRY-2, evaluated the efficacy and safety of BIC/LEN across 2 clinically relevant switch populations: adults with HIV switching to an STR from complex antitetroviral (ARV) regimens and adults with HIV receiving a standard-of-care STR who may be interested in an alternative treatment option.12,13 Section 4 has details on the ARTISTRY clinical trials.

3. MECHANISM OF ACTION AND CLINICAL RATIONALE

3.1. Rationale for the BIC/LEN Combination

The coformulation of bictegravir (BIC) and lenacapavir (LEN) combines 2 antiretroviral agents that act at different stages of the HIV replication cycle. BIC inhibits viral DNA integration,10,14 while LEN inhibits multiple capsid-dependent steps of the viral life cycle.15 Together, these complementary mechanisms provide a multistage approach to suppressing HIV replication.12

3.1.1. Bictegravir

Bictegravir (BIC) is a second-generation INSTI that inhibits HIV-1 integrase strand transfer, blocking the integration of viral DNA into host genomic DNA, an essential step in viral replication.10

3.1.2. Lenacapavir

Lenacapavir (LEN) is a first-in-class multistage selective inhibitor of HIV-1 capsid function. LEN disrupts the HIV-1 capsid at multiple stages of the HIV life cycle: capsid-mediated nuclear uptake of HIV-1 proviral DNA, virus assembly and release, and capsid core formation.10

3.2. Pharmacology of the Oral Loading Dose

Lenacapavir has low aqueous solubility and undergoes significant first-pass metabolism mediated by CYP3A and intestinal P-glycoprotein (P-gp). Without adequate drug concentrations at the intestinal level, oral bioavailability of the maintenance dose would be insufficient to achieve therapeutic plasma levels promptly.16

The 2-day oral initiation dose 600 mg SUNLENCA (lenacapavir) (2 Å~ 300 mg) on days 1 and 2 serves as an initiation regimen that helps rapidly achieve therapeutic drug concentrations.17 The 2-day initiation dose should be taken in combination with 1 BIC/LEN tablet daily. This initiation dose enables the lenacapavir component within the BIC/LEN 75-mg/50-mg fixed-dose combination to achieve therapeutic lenacapavir concentrations rapidly.17 According to the US prescribing information, a Tmax of approximately 4 hours means that peak lenacapavir plasma concentrations will be achieved in about 4 hours after an oral dose, reflecting the time required for absorption and systemic exposure.10

4. KEY EFFICACY AND SAFETY EVIDENCE

4.1. ARTISTRY-1: Evaluating BIC/LEN as an STR for Virologically Suppressed Adults on Complex Regimens

ARTISTRY-1 (NCT05502341) was a global, randomized, open-label, active-controlled phase 3 study designed to evaluate the efficacy and safety of switching to BIC/LEN from complex ARV regimen in virologically suppressed adults with HIV.12 Complex ARV regimens were defined as regimens containing a boosted protease inhibitor or non-nucleoside reverse transcriptase inhibitor plus 1 or more third agents from another class, other than nucleoside reverse transcriptase inhibitor, and regimens requiring multiple tablets or more-than-once-daily dosing, or regimens containing both parenteral and oral antiretroviral therapy (excluding a complete long-acting injectable) due to resistance, intolerance, drug-drug interactions, or contraindications to available single-tablet regimens. Adults with HIV-1 RNA <50 copies/mL and on complex ARV regimen for at least 6 months were randomly assigned 2:1 to switch to BIC/LEN (n=371) or continue their existing complex ARV regimen (n=186). All participants assigned to BIC/LEN received oral lenacapavir loading doses on days 1 and 2 before transitioning to maintenance therapy.

The primary objective of ARTISTRY-1 was to determine whether switching to BIC/LEN was noninferior to continuing a complex ARV regimen for maintaining virologic suppression through week 48, as assessed by the proportion of participants with HIV-1 RNA ≥50 copies/mL using the FDA Snapshot algorithm and noninferiority margin of 4%. Secondary objectives included evaluation of the proportion of participants with HIV-1 RNA <50 copies/mL at week 48 and treatment-emergent adverse events through week 48.

At week 48, switching to BIC/LEN demonstrated noninferior efficacy compared with continuing complex ARV regimen. HIV-1 RNA ≥50 copies/mL was observed in 1% of participants receiving BIC/LEN and 1% of participants continuing their complex ARV regimen (treatment difference −0.3%; 95% CI, −2.3% to 1.8%). The percentage of participants with HIV-1 RNA < 50 copies/mL were 96% with BIXLENVO and 94% with the stable baseline regimen.10 These findings demonstrated that switching to BIC/LEN maintained virologic suppression while reducing regimen complexity to a once-daily maintenance STR.

The most common adverse reactions reported with BIC/LEN were headache (4%), nausea (3%), and diarrhea (2%). Laboratory abnormalities included elevations in aspartate aminotransferase (AST) and alanine aminotransferase (ALT), with AST/ALT elevations ≥1.25 ULN reported in 14% of participants receiving BIC/LEN compared with 2% of participants remaining on their stable baseline regimen.10 These laboratory abnormalities were primarily grade 1 or 2.10

In ARTISTRY-1, two of 371 (0.5%) participants in the BIC/LEN group met the criteria for resistance testing (HIV-1 RNA ≥ 200 copies/mL at confirmed virologic failure or last visit on study drugs) through week 48. Resistance analyses showed that 1 of these participants had no detectable capsid or integrase resistance. The other participant had no detectable resistance in capsid and had transient emergence of a Q148R substitution in integrase at low level (13% mutant) at week 24 that was associated with a 1.2-fold reduction in bictegravir susceptibility; this substitution was not detected at week 48.10

4.2. ARTISTRY-2: Evaluating BIC/LEN as a Switch Option for Virologically Suppressed Adults Receiving B/F/TAF

ARTISTRY-2 (NCT06333808) was a randomized, doubleblind, active-controlled, noninferiority phase 3 trial that evaluated switching virologically suppressed adults from bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) to BIC/LEN.13 Adults with HIV-1 RNA <50 copies/mL for at least 6 months and who were receiving B/F/TAF were randomly assigned 2:1 to switch to BIC/LEN (n=383) or continue B/F/TAF (n=191). Participants assigned to BIC/LEN received oral lenacapavir initiation doses on days 1 and 2 before transitioning to maintenance therapy.

At week 48, BIC/LEN demonstrated noninferior efficacy compared with continued B/F/TAF. HIV-1 RNA ≥50 copies/mL occurred in 0.5% (2/383) of participants who switched to BIC/LEN and 0.5% (1/191) of participants who continued B/F/TAF, meeting the predefined criterion for noninferiority. Virologic suppression (HIV-1 RNA <50 copies/mL) was maintained in 94.8% (363/383) of participants receiving BIC/LEN and 95.8% (183/191) of participants receiving B/F/TAF.10 These findings demonstrated that switching from B/F/TAF to BIC/LEN maintained virologic suppression through week 48.

In ARTISTRY-2, the most common adverse reactions reported with BIC/LEN were headache (4%), nausea (3%), and diarrhea (2%). AST/ALT elevations ≥1.25 ULN were reported in 13% of participants receiving BIC/LEN compared with 6% receiving B/F/TAF. These elevations were primarily grade 1 laboratory abnormalities, with very low rates of grade 3 or grade 4 events. No new hepatic safety signal was identified during the study.10

Two of the 383 (0.5%) participants in the BIC/LEN group met the criteria for resistance testing (HIV-1 RNA ≥ 200 copies/mL at confirmed virologic failure or last visit on study drugs) through week 48. In 1 participant, no lenacapavir resistance substitutions were detected in capsid and an R263K substitution in integrase was detected that had a 2-fold reduction in susceptibility to bictegravir in comparison to wild type. The second participant had no detectable emergence of resistance in capsid or integrase.10

5. DRUG-DRUG INTERACTIONS

Drug-drug interactions are common in HIV treatment and may represent an important consideration when optimizing antiretroviral therapy. When optimizing an antiretroviral regimen, several factors, including patient needs, treatment goals, and concerns with the current regimen, should be taken into consideration to support the maintenance of virologic suppression.18 The drug-drug interaction profile of BIXLENVO is well established and recommendations vary by concomitant medication.10

Bictegravir (BIC), a component of BIXLENVO, inhibits organic cation transporter 2 (OCT2) and multidrug and toxin extrusion transporter 1 (MATE1) in vitro. Coadministration of BIC with drugs that are substrates of OCT2 and MATE1 (eg, dofetilide) may increase their plasma concentrations.10 Lenacapavir (LEN), a component of BIXLENVO, is a moderate inhibitor of CYP3A and a P-gp inhibitor.

Coadministration of LEN with sensitive substrates of CYP3A or P-gp may increase the concentrations of these substrates and result in increased risk of their adverse events.10

Concomitant administration of BIXLENVO with strong CYP3A inducers is contraindicated. Concomitant administration of BIXLENVO with moderate CYP3A inducers is not recommended.10

6. CONSIDERATIONS FOR PHARMACISTS

Pharmacists across clinical, specialty, community, and retail settings may encounter BIXLENVO at different points in the process such as medication review, prescription processing, dispensing, and patient counseling. The following considerations summarize information from the BIXLENVO US prescribing information and applicable HIV treatment guidelines. They are intended to support awareness of labeled use, dosing, drug interactions, treatment continuity, and access-related pharmacy workflows.

6.1. Considerations When an Antiretroviral Regimen Is Changed

  • The HHS guidelines state that the fundamental principle of regimen optimization in the setting of viral suppression is to maintain viral suppression without jeopardizing future treatment options. The guidelines recommend reviewing the individual’s complete antiretroviral history, including prior virologic responses, treatment-associated toxicities or intolerances, and cumulative resistance test results, before selecting a new regimen.4
  • BIXLENVO is indicated as a complete regimen to replace the current antiretroviral regimen in adults with HIV-1 who are virologically suppressed, defined as HIV-1 RNA < 50 copies/mL, on a stable antiretroviral regimen and who have no known or suspected resistance to the individual components of BIXLENVO. It is not indicated for treatment-naive individuals or for individuals who do not meet the labeled criteria.10
  • ARTISTRY-1 evaluated switching to BIXLENVO from a complex stable baseline regimen, whereas ARTISTRY-2 evaluated switching to BIXLENVO from BIKTARVY. At week 48, HIV-1 RNA ≥50 copies/mL was reported in 1% of participants in each treatment group in both studies. Because the trials differed in their designs and populations, findings should be interpreted within each study rather than compared directly across studies.12,13

6.2. Initiation, Prescription, and Dispensing

  • BIXLENVO has a 2-day initiation regimen that includes both BIXLENVO and oral SUNLENCA. On day 1 and day 2, the labeled dose is 1 BIXLENVO 75-mg/50-mg tablet plus SUNLENCA 600 mg, administered as 2 300-mg tablets. Beginning on day 3, the maintenance dose is 1 BIXLENVO 75-mg/50-mg tablet once daily. Both BIXLENVO and SUNLENCA may be taken with or without food.10
  • The initiation regimen for BIC/LEN requires 2 separate prescriptions, while the maintenance regimen requires only 1 prescription.
  • Pharmacy review of the prescriptions can help identify whether the products required for both initiation days are available before treatment begins. This may be particularly relevant when BIXLENVO and SUNLENCA are processed or dispensed separately.

6.3. Missed Initiation Dose

During the initiation period, if the day 1 or day 2 doses of BIXLENVO or SUNLENCA are missed, patients should take them as soon as possible. Patients should not take day 1 and day 2 doses of SUNLENCA on the same day.

6.4. Missed Maintenance Dose

If a maintenance dose of BIXLENVO is missed, patients should take it as soon as possible. If more than 7 days have elapsed since the last maintenance dose, restart the initiation dosage regimen from day 1 if clinically appropriate to continue BIXLENVO treatment.

6.5. Drug Interactions

  • The BIXLENVO US prescribing information advises consideration of potential drug interactions before and during treatment and recommends consulting the full US prescribing information for contraindications and potentially significant drug interactions. Because BIXLENVO is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 is not recommended.10
  • BIXLENVO is contraindicated with dofetilide and strong CYP3A inducers. Medication review should include prescription medications, over-the-counter products, vitamins, and herbal supplements, including St. John’s wort.10
  • Recommendations differ across individual concomitant medications. For example, the US prescribing information provides drug-specific guidance for phosphodiesterase-5 inhibitors based on the agent and indication. The BIXLENVO US prescribing information and the US prescribing information for the concomitant medication should be consulted for the applicable recommendation. A broad statement that all phosphodiesterase-5 inhibitors “increase BIXLENVO concentrations” should not be used.
  • Medication reconciliation at treatment initiation and when medications are added, discontinued, or changed provides an opportunity to identify potential interactions and communicate questions to the prescribing team. This is consistent with the label’s direction to consider potential interactions before and during BIXLENVO treatment.

6.6. Access and Coordination of Therapy

  • Coverage requirements, prior authorization processes, and dispensing pathways may vary by payer, pharmacy, and patient circumstances. Pharmacy teams may coordinate with the prescriber and other members of the health care team to help clarify coverage requirements and whether both components of the initiation regimen can be obtained before treatment begins.
  • When applicable, patients may be directed to available insurance-navigation, copay-support, or patient-assistance resources based on program eligibility and current program terms.
  • On Days 1 and 2, the regimen requires both BIXLENVO and oral SUNLENCA; BIXLENVO alone is administered once daily beginning on day 3. Access considerations should not alter the labeled initiation regimen.
REFERENCES
1. Julg B, Bogner JR. Atripla: HIV therapy in one pill. Ther Clin Risk Manag. 2008;4(3):573-577.
2. Atripla. Prescribing information. Gilead Sciences, Inc; 2020. Accessed August 31, 2026. https://www.gilead.com/-/media/files/pdfs/medicines/hiv/atripla/atripla_pi.pdf
3. US Food and Drug Administration approves Atripla, the first once-daily single-tablet regimen for adults with HIV-1 infection. News release. Gilead Sciences, Inc. July 12, 2006. Accessed August 31, 2026. https://www.gilead.com/news/news-details/2006/us-food-and-drug-administration-fda-approves-atriplatm-efavirenz-600-mg-emtricitabine-200-mg-tenofovir-disoproxil-fumarate-300-mg-the-first-once-daily-single-tablet-regimen-for-adults-with-hiv
4. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV. HHS. Updated October 27, 2026. Accessed August 31, 2026. https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv
5. Trickey A, Sabin CA, Burkholder G, et al. Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies. Lancet HIV. 2023;10(5):e295-e307. doi:10.1016/S2352-3018(23)00028-0.
6. Laboratory testing for initial assessment and monitoring of people with HIV. HHS. Updated October 27, 2026. Accessed August 31, 2026. https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/tests-initial-assessment-follow-up
7. Paudel M, Prajapati G, Buysman EK, et al. Comorbidity and polypharmacy among people with HIV stratified by age, sex, and race. HIV Res Clin Pract. 2024;25(1):2361176. doi:10.1080/25787489.2024.2361176.
8. O’Connor SM, Song R, Viguerie A, et al. Projected increases in older people with HIV in the United States through 2040. Open Forum Infect Dis. 2025;12(11):ofaf656. doi:10.1093/ofid/ofaf656.
9. U.S. FDA approves Gilead’s Bixlenvo, a new once-daily single-tablet option for virologically suppressed adults with HIV, including those on complex regimens. News release. Gilead Sciences, Inc. August 27, 2026. Accessed September 3, 2026. https://www.gilead.com/news/news-details/2026/u-s--fda-approves-gileads-bixlenvo-a-new-once-dailysingle-tablet-option-for-virologically-suppressed-adults-with-hiv-including--those-on-complex-regimens
10. Public health strategies for pharmacists to improve health for people with chronic cardiovascular disease. CDC. Updated September 8, 2026. Accessed September 3, 2026. https://www.cdc.gov/cardiovascular-resources/php/public-health-strategy/index.html
11. Bixlenvo. Prescribing information. Gilead Sciences, Inc; 2026. Accessed September 3, 2026. https://www.gilead.com/-/media/files/pdfs/medicines/hiv/bixlenvo/bixlenvo_pi.pdf
12. Orkin C, Ruane PJ, Hedgcock M, et al; ARTISTRY-1 Study Group. Switch to single-tablet bictegravir-lenacapavir from a complex HIV regimen (ARTISTRY-1): a randomised, open-label, phase 3 clinical trial. Lancet. 2026;407(10535):1249-1258. doi:10.1016/S0140-6736(26)00307-7
13. Meissner EG, Ramgopal M, Ruane PJ, et al; ARTISTRY-2 Study Group. Safety and efficacy of switching to bictegravir-lenacapavir versus continuing bictegravir-emtricitabine-tenofovir alafenamide in virologically suppressed people with HIV-1 (ARTISTRY-2): a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet HIV. 2026;13(8):e538-e547. doi:10.1016/S2352-3018(26)00078-0
14. Tsiang M, Jones GS, Goldsmith J, et al. Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile. Antimicrob Agents Chemother. 2016;60(12):7086-7097. doi:10.1128/AAC.01474-16
15. Link JO, Rhee MS, Tse WC, et al. Clinical targeting of HIV capsid with a long-acting small molecule. Nature. 2020;584(7822):614-618. doi:10.1038/s41586-020-2443-1
16. Weber E, Subramanian R, Rowe W, et al. Pharmacokinetics, disposition, and biotransformation of [.⁴C]lenacapavir, a novel, first-in-class, selective inhibitor of HIV-1 capsid function, in healthy participants following a single intravenous infusion. Clin Pharmacokinet. 2024;63(2):241-253. doi:10.1007/s40262-023-01328-1
17. Arora P, Oh E, Montezuma-Rusca JM, et al. Pharmacokinetic analysis of oral once-daily bictegravir plus lenacapavir administered separately and as a bictegravir/lenacapavir 75 mg/50 mg single-tablet regimen to support phase 3 dose selection. Poster presented at: HIV Drug Therapy Glasgow; November 10-13, 2024; Glasgow, Scotland. Poster P049.
18. Optimizing antiretroviral therapy in the setting of viral suppression. HHS. Updated September 12, 2024. Accessed June 29, 2026. https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/optimizing-antiretroviral-therapy
19. Sunlenca. Prescribing information. Gilead Sciences, Inc; 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215974s014lbl.pdf

Related to this article